Market Trends of Cardiac Mapping Industry
Atrial Fibrillation Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Cardiac mapping facilitates the identification of irregular heart rhythms (arrhythmias), including atrial fibrillation (AF). The increasing cases of heart failure, stroke, and other complications associated with AF underscores the importance of cardiac mapping, leading to substantial market growth projections for this segment.
The atrial fibrillation market is poised for substantial growth, driven by factors such as the rising prevalence of atrial fibrillation and increased demand for cardiac mapping in its treatment. Atrial fibrillation arises from a combination of a trigger that initiates an irregular heartbeat and a substrate that sustains it.
The high prevalence of atrial fibrillation (AFib) is a crucial driver for the growth of the cardiac mapping market. For instance, according to the data updated by the Centers for Disease Control and Prevention (CDC) in May 2024, 12.1 million Americans are expected to be affected by atrial fibrillation by 2030, and over 454,000 hospitalizations occur annually with atrial fibrillation as the primary diagnosis. Cardiac mapping is crucial for optimizing ablation techniques, allowing doctors to pinpoint triggers and substrates causing AFib and deliver targeted treatment. Thus, the high prevalence of atrial fibrillation globally is anticipated to fuel the market's growth over the forecast period.
Additionally, manufacturers focus on developing cardiac mapping and launching the product in the market. For instance, in August 2023, GE Healthcare launched CardioVisio, a digital tool designed to assist clinicians in visualizing longitudinal data essential for tracking the progression of Atrial Fibrillation (AFib) from diverse sources. Additionally, it offers evidence-based clinical decision support, aligning with the latest AFib guidelines. Thus, the rising initiatives by manufacturers, such as launches, are expected to drive the market's growth during the forecast period.
Furthermore, technological advancements in arrhythmia management are expected to drive market growth during the forecast period. For instance, according to an article published in Intechopen journal in May 2022, the advent of 3D electroanatomic mapping (EAM) and high-definition (HD) mapping significantly enhanced the safety and efficacy of ablation procedures, resulting in reduced procedural time and fluoroscopy exposure. Hence, the segment is expected to witness significant growth over the forecast period due to factors such as growing cases of atrial fibrillation and a rise in technological advances in cardiac mapping.
North America is Anticipated to Hold a Notable Market Share Over the Forecast Period
North America is expected to hold a significant market share during the forecast period due to the increase in healthcare expenditures, the growing burden of cardiac diseases, and the rise in product launches across North America. For instance, according to the American Heart Association (AHA), in February 2023, cardiac arrest in out-of-hospital remained a significant public health concern, accounting for approximately 350,000 fatalities annually in the United States. Additionally, as per the article published by PubMed in October 2022, an estimated 1000 adults in the United States experienced out-of-hospital cardiac arrest (OHCA) daily in 2022. Hence, the substantial prevalence of cardiac arrest in adults is anticipated to fuel market expansion during the projected period.
Similarly, the collaboration between the Canadian Institute for Health Information (CIHI) and the Canadian Cardiovascular Society (CCS) on the Cardiac Care Quality Indicators (CCQI) project has contributed to monitoring and improving critical areas related to cardiac care interventions across Canada. As a result, such initiatives are expected to drive market growth in the region during the forecast period.
Additionally, the expanding number of product approvals for cardiac mapping in North America is anticipated to be a key driver for the market's growth. For instance, in January 2022, Abbott secured FDA clearance for the EnSITE X EP system with EnSite Omnipolar Technology, a cardiac mapping platform. With the increasing prevalence of cardiac diseases and the proliferation of technological advancements, North America is expected to dominate a substantial portion of the global market throughout the forecast period.
